DeepMed Research

Pharmacosmos A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pharmacosmos.com

Clinical Trials

Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

Phase 3

Not yet recruiting

Conditions: Chronic Heart Failure
Iron Deficiencies

Interventions: Drug: Ferric Derisomaltose

First Posted Date: 2025-04-16

Last Posted Date: 2025-04-16

Lead Sponsor: Pharmacosmos A/S

Target Recruit Count: 1900

Registration Number: NCT06929806

A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia

Phase 2

Recruiting

Conditions: Beta Thalassemia Major Anemia

Interventions: Drug: SP-420

First Posted Date: 2023-01-23

Last Posted Date: 2023-10-23

Lead Sponsor: Pharmacosmos A/S

Target Recruit Count: 90

Registration Number: NCT05693909

Locations: 🇩🇰
Pharmacosmos Investigational Site, Copenhagen, Denmark

A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation

Phase 4

Not yet recruiting

Conditions: Malignant Lymphoma
Multiple Myeloma

Interventions: Other: Pentaisomaltose

First Posted Date: 2022-09-19

Last Posted Date: 2024-04-03

Lead Sponsor: Pharmacosmos A/S

Target Recruit Count: 150

Registration Number: NCT05545202

Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age with Iron Deficiency Anemia

Phase 3

Recruiting

Conditions: Iron Deficiency, Anaemia in Children

Interventions: Drug: Ferric Derisomaltose

First Posted Date: 2022-01-05

Last Posted Date: 2025-02-24

Lead Sponsor: Pharmacosmos A/S

Target Recruit Count: 200

Registration Number: NCT05179226

Locations: 🇺🇸
Pharmacosmos Investigational Site, Miami, Florida, United States

A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

Phase 4

Completed

Conditions: IBD

Interventions: Drug: Iron Isomaltoside
Drug: Ferric Carboxymaltose

First Posted Date: 2018-03-15

Last Posted Date: 2021-02-21

Lead Sponsor: Pharmacosmos A/S

Target Recruit Count: 97

Registration Number: NCT03466983

Locations: 🇩🇰
Pharmacosmos Investigational Site, Silkeborg, Denmark

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Phase 3

Completed

Conditions: Iron Deficiency Anaemia
Iron Deficiency Anemia

Interventions: Drug: Iron isomaltoside/ferric derisomaltose
Drug: Ferric carboxymaltose

First Posted Date: 2017-08-03

Last Posted Date: 2020-02-25

Lead Sponsor: Pharmacosmos A/S

Target Recruit Count: 123

Registration Number: NCT03238911

Locations: 🇺🇸
Pharmacosmos Investigational Site, Leesburg, Virginia, United States
🇺🇸
Pharmacosmos Investigational Site 2, Miami, Florida, United States
🇺🇸
Pharmacosmos Investigational Site 1, Miami, Florida, United States

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Phase 3

Completed

Conditions: Iron Deficiency Anaemia
Iron Deficiency Anemia

Interventions: Drug: Iron isomaltoside/ferric derisomaltose
Drug: Ferric carboxymaltose

First Posted Date: 2017-08-02

Last Posted Date: 2020-02-25

Lead Sponsor: Pharmacosmos A/S

Target Recruit Count: 122

Registration Number: NCT03237065

Locations: 🇺🇸
Pharmacosmos Investigational Site, Winston-Salem, North Carolina, United States
🇺🇸
Pharmacosmos investigational Site, Flint, Michigan, United States

Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.

Phase 4

Completed

Conditions: Iron Deficiency Anemia of Pregnancy

Interventions: Drug: ferrous fumarate with ascorbic acid
Drug: Iron Isomaltoside 1000

First Posted Date: 2017-06-15

Last Posted Date: 2020-11-13

Lead Sponsor: Pharmacosmos A/S

Target Recruit Count: 201

Registration Number: NCT03188445

Locations: 🇩🇰
Phamacosmos Investigational site, Hvidovre, Sjaeland, Denmark

Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)

Phase 1

Completed

Conditions: Anemia, Iron Deficiency
Anemia
Deficiency Diseases
Hematologic Disease
Iron Metabolism Disorders

Interventions: Drug: Iron Isomaltoside

First Posted Date: 2017-01-06

Last Posted Date: 2017-12-12

Lead Sponsor: Pharmacosmos A/S

Target Recruit Count: 24

Registration Number: NCT03013439

Locations: 🇯🇵
Ikebukuro, Tokyo, Japan

An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

Phase 3

Completed

Conditions: Iron Deficiency Anaemia
Iron Deficiency Anemia

Interventions: Drug: Iron isomaltoside/ferric derisomaltose

First Posted Date: 2016-11-11

Last Posted Date: 2020-03-10

Lead Sponsor: Pharmacosmos A/S

Target Recruit Count: 103

Registration Number: NCT02962648

Locations: 🇺🇸
Pharmacosmos Investigational Site, Houston, Texas, United States
🇺🇸
Pharmacosmos Investigational Site 1, San Antonio, Texas, United States
🇺🇸
Pharmacosmos Investigational Site 2, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy